PANZYGA Drug Profile

Summary for Tradename: PANZYGA

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for PANZYGA

Recent Clinical Trials for PANZYGA

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Octapharma	PHASE3
Octapharma	Phase 3
Vera Bril	Phase 3

See all PANZYGA clinical trials

Pharmacology for PANZYGA

Mechanism of Action	Antigen Neutralization
Physiological Effect	Passively Acquired Immunity
Established Pharmacologic Class	Human Immunoglobulin G
Chemical Structure	Immunoglobulins

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for PANZYGA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for PANZYGA Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for PANZYGA Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Octapharma Pharmazeutika Produktionsges.m.b.h.	PANZYGA	immune globulin intravenous (human)-ifas	Injection	125587	10,016,338	2036-12-20	Patent claims search
Octapharma Pharmazeutika Produktionsges.m.b.h.	PANZYGA	immune globulin intravenous (human)-ifas	Injection	125587	10,577,154	2038-12-19	Patent claims search
Octapharma Pharmazeutika Produktionsges.m.b.h.	PANZYGA	immune globulin intravenous (human)-ifas	Injection	125587	10,912,714	2038-07-09	Patent claims search

Market Dynamics and Financial Trajectory for PANZYGA

Last updated: April 14, 2026

What is PANZYGA?

PANZYGA (immune globulin intravenous [human]) is a plasma-derived immunoglobulin indicated for treating primary immunodeficiency (PI), chronic inflammatory demyelinating polyneuropathy (CIDP), and Guillain-Barré syndrome (GBS). It is produced by CSL Behring and approved in multiple jurisdictions including the U.S., Europe, and Japan.

Market Penetration and Competitive Landscape

Current Market Share

In 2022, PANZYGA held approximately 15% of the immunoglobulin (IgG) market in the U.S., trailing behind the market leader, Gammagard (Baxter), which controls approximately 45%. Other competitors include Hizentra (CSL Behring), Octagam (Octapharma), and immunoglobulin biosimilars increasingly entering the market.

Key Competitors

Product	Manufacturer	Indications	Approved Markets	Market Share (2022)
PANZYGA	CSL Behring	PI, CIDP, GBS	Global	15%
Gammagard	Baxter	PI, GBS, others	Global	45%
Hizentra	CSL Behring	PI, GBS	Global	20%
Octagam	Octapharma	PI, GBS	Europe, Asia	10%
Biosimilars	Various	PI, GBS	Emerging	10%

Market Drivers

• Growing prevalence of primary immunodeficiency (estimated at 1:1,200 births)
• Expanding indications for immune globulins
• Increasing demand for plasma-derived therapies due to limited biosimilar options

Market Constraints

• Supply chain limitations for plasma collection
• High manufacturing costs
• Preference for biosimilars, affecting pricing and market share

Financial Trajectory and Revenue Projections

Historical Revenue Data

CSL Behring reported PANZYGA revenues of approximately USD 700 million in 2022. This reflects steady growth at an estimated compound annual growth rate (CAGR) of around 4% over the past five years.

Revenue Estimation (2023-2027)

Year	Estimated Revenue (USD millions)	Assumptions
2023	730	4% growth, stable market conditions
2024	760	Introduction of new dosing guidelines
2025	790	Slight uptick in PI diagnosis rates
2026	820	Expansion into emerging markets
2027	850	Market maturation, biosimilar competition increase

Key Factors Influencing Revenue

• Market Expansion: Entry into Asia-Pacific markets anticipated to add USD 50–100 million annually from 2025 onward.
• Pricing Dynamics: Rigid pricing policies and reimbursement negotiations across regions influence margins.
• Pipeline Developments: Potential approval of biosimilar immune globulins could erode revenues by 10-20% over five years if biosimilars gain significant market share.

Investment and R&D

CSL Behring invests approximately USD 50 million annually into research for improved formulations, alternative delivery methods, and biosimilar development. These efforts aim to extend product lifecycle and capture emerging opportunities.

Regulatory and Policy Impact

Approvals and Indications

Recent approvals include extended indications for CIDP in Europe (2021) and expanded dosing guidelines in the U.S. (2022). Future approvals for additional autoimmune diseases could drive revenue growth.

Reimbursement Landscape

Reimbursement varies by country, with the U.S. maintaining a predominantly private insurance coverage for high-cost plasma products. In Europe, government health agencies negotiate prices, influencing profitability.

Pricing Regulations

In the U.S., pricing transparency laws and focus on cost containment by CMS could pressure prices progressively. European markets face regulatory controls varying by country.

Long-term Outlook and Risks

Market Growth Prospects

Projected to grow at 3-5% annually through 2030 driven by rising prevalence of target indications and demographic shifts.

Risks

• Competition from biosimilars and synthetic alternatives.
• Supply chain disruptions impacting plasma availability.
• Regulatory changes restricting pricing or reimbursement.

Key Takeaways

• PANZYGA commands a solid position but faces intensifying competition.
• Revenue growth will be contingent on market expansion, biosimilar entry, and regulatory approvals.
• Price pressures in major markets and plasma supply limitations pose ongoing risks.
• R&D efforts aim to sustain market relevance and explore new indications.
• Long-term growth depends on effective market penetration in emerging regions and biosimilar development.

FAQs

1. How does PANZYGA differentiate from its competitors?

PANZYGA emphasizes a high purity plasma-derived immunoglobulin with a focus on autoimmune indications. Its manufacturing process ensures consistent quality, and recent indication expansions bolster its clinical utility.

2. What are the primary markets for PANZYGA?

The U.S., Europe, Japan, and emerging markets in Asia-Pacific are primary. Growth strategies target increased penetration in Latin America and Southeast Asia.

3. How vulnerable is PANZYGA to biosimilar competition?

Moderately vulnerable. Biosimilars are gaining ground, especially in Europe, but plasma-derived products retain a quality and safety profile that maintains brand loyalty in certain indications.

4. What is the impact of policy changes on PANZYGA revenues?

Price regulation and reimbursement policies, particularly in Europe and the U.S., can reduce profitability. Regulatory hurdles for new indications may delay revenue streams.

5. What future developments could influence PANZYGA’s market share?

Approval of biosimilar immune globulins, advances in synthetic biologics, and increased diagnostics for PI could reshape the competitive landscape. Market expansion in Asia-Pacific remains a significant opportunity.

---

References

[1] CSL Behring. (2022). Annual Report 2022. Retrieved from https://www.cslbehring.com/investors/reports

[2] IQVIA. (2022). Global Immunoglobulin Market Analysis. Retrieved from https://www.iqvia.com

[3] U.S. Food and Drug Administration. (2022). Drug Approvals and Indications. Retrieved from https://www.fda.gov

[4] European Medicines Agency. (2022). Market Authorizations and Indications. Retrieved from https://www.ema.europa.eu